OLR1 Antibody

What is OLR1/LOX-1 and why are antibodies against it important for research?

OLR1 (Oxidized Low-Density Lipoprotein Receptor 1), also known as LOX-1 (Lectin-like Oxidized LDL Receptor-1) or CLEC8A, is a type II transmembrane receptor belonging to the C-type lectin superfamily. It functions as the first identified member of the class E scavenger receptor subfamily (SR-E). OLR1/LOX-1 plays a critical role in binding and internalizing multiple structurally unrelated macromolecules including oxidized LDL, advanced glycation end products (AGE), activated platelets, bacteria, apoptotic cells, and heat shock proteins . Antibodies against OLR1/LOX-1 are essential research tools that enable scientists to detect, quantify, and characterize this receptor's expression and function in various disease states, particularly atherosclerosis, cancer, and inflammatory conditions .

How does the OLR1/LOX-1 antibody differ from other scavenger receptor antibodies?

OLR1/LOX-1 antibodies are specifically designed to target the unique epitopes of the OLR1 receptor, distinguishing it from other scavenger receptor family members. Unlike antibodies against other scavenger receptors, OLR1 antibodies recognize the characteristic C-type lectin domain structure of the receptor. The specificity of these antibodies is critical, as evidenced by manufacturers' validation procedures that confirm no cross-reactivity with other proteins . For example, the polyclonal antibody described in the search results targets a synthetic peptide corresponding to a sequence in the middle region of human LOX-1/OLR1 that differs from the related rat sequence by thirteen amino acids, ensuring species specificity . This specificity allows researchers to distinguish OLR1/LOX-1's unique roles in various physiological and pathological processes from those of other scavenger receptors.

What is the molecular weight of OLR1/LOX-1 protein, and why might it vary in Western blot results?

While the calculated molecular weight of OLR1/LOX-1 is approximately 31 kDa, it is typically observed at approximately 38-40 kDa on Western blots . This discrepancy between calculated and observed molecular weights is important for researchers to understand when interpreting their results. Several factors may contribute to this difference:

• Post-translational modifications, particularly glycosylation, which can significantly increase the apparent molecular weight

• The presence of the transmembrane domain, which may affect protein migration

• Formation of protein complexes that are not fully denatured during sample preparation

• Different isoforms resulting from alternative splicing

In Western blot analysis of human placenta tissue lysate, for example, LOX-1/OLR1 antibody detected a specific band at approximately 38 kDa despite the expected band size being 31 kDa . Understanding these variations is crucial for accurate data interpretation and avoiding false negative results when analyzing OLR1/LOX-1 expression in experimental samples.

What are the optimal conditions for using OLR1/LOX-1 antibodies in immunohistochemistry?

For optimal immunohistochemical detection of OLR1/LOX-1, researchers should consider the following methodological approaches:

• Fixation and Processing: Immersion-fixed, paraffin-embedded sections yield reliable results. For example, successful detection has been demonstrated in human placenta sections using this method .

• Antibody Concentration: A concentration of 1 μg/mL has been validated for overnight incubation at 4°C. Researchers should optimize this concentration for their specific tissue samples .

• Detection System: For goat polyclonal antibodies like AF1798, an appropriate detection system such as Anti-Goat HRP-DAB Cell & Tissue Staining Kit has been validated .

• Antigen Retrieval: Although not explicitly mentioned in the search results, antigen retrieval is typically necessary for paraffin sections and should be optimized based on the specific tissue.

• Controls: Include positive control tissues (such as human placenta, where staining localizes to cytotrophoblasts) and negative controls to validate staining specificity .

• Counterstaining: Hematoxylin counterstaining provides good contrast with DAB-labeled primary staining .

These conditions should serve as a starting point, with optimization necessary for different tissue types and experimental questions.

What are the recommended protocols for Western blot analysis of OLR1/LOX-1?

For robust Western blot analysis of OLR1/LOX-1, researchers should follow these methodological guidelines:

• Sample Preparation: Load approximately 50 μg of sample under reducing conditions for optimal detection .

• Electrophoresis Conditions: Run samples on a 5-20% SDS-PAGE gel at 70V (stacking gel) followed by 90V (resolving gel) for 2-3 hours to achieve good protein separation .

• Transfer Conditions: Transfer proteins to a nitrocellulose membrane at 150 mA for 50-90 minutes to ensure complete transfer of the target protein .

• Blocking: Block the membrane with 5% non-fat milk in TBS for 1.5 hours at room temperature to minimize non-specific binding .

• Primary Antibody Incubation: Incubate with anti-LOX-1/OLR1 antibody at 0.5 μg/mL overnight at 4°C. For polyclonal antibodies (catalog # A00760-1), concentrations between 0.1-0.5 μg/ml have been validated .

• Washing: Wash thoroughly with TBS-0.1% Tween, 3 times for 5 minutes each to reduce background signal .

• Secondary Antibody: Probe with an appropriate secondary antibody (e.g., goat anti-rabbit IgG-HRP) at a dilution of 1:10000 for 1.5 hours at room temperature .

• Detection: Develop the signal using an enhanced chemiluminescent detection system for optimal sensitivity .

• Expected Results: Anticipate detecting OLR1/LOX-1 at approximately 38 kDa despite the calculated size of 31 kDa due to post-translational modifications .

Human placenta tissue lysate serves as an effective positive control for validating the Western blot protocol .

How can researchers validate the specificity of OLR1/LOX-1 antibodies in their experimental systems?

Validating antibody specificity is critical for generating reliable data. Researchers should implement the following methodological approaches to confirm OLR1/LOX-1 antibody specificity:

• Positive and Negative Controls: Include known positive control samples (e.g., human placenta for OLR1/LOX-1) and negative control tissues where the target protein is not expressed .

• Blocking Peptide Competition: Perform parallel experiments with and without pre-incubation of the antibody with its specific immunogenic peptide. Signal elimination in the presence of the blocking peptide confirms specificity .

• Knockdown/Knockout Validation: Utilize cellular systems with OLR1/LOX-1 knockdown or knockout. For example, the search results mention stable prostate cancer cell lines with LOX-1 knockdown using shRNA against OLR1, which provide excellent negative controls .

• Overexpression Systems: Compare antibody reactivity in cells with and without OLR1/LOX-1 overexpression. The search results describe human prostate cancer cell clones with LOX-1 overexpression that could serve this purpose .

• Multiple Antibody Approach: Use multiple antibodies targeting different epitopes of OLR1/LOX-1 to confirm consistent expression patterns.

• Multiple Detection Methods: Validate findings using complementary techniques such as Western blot, immunohistochemistry, and RT-PCR to confirm expression at both protein and mRNA levels .

Implementation of these validation strategies provides robust confirmation of antibody specificity, ensuring reliable experimental outcomes and interpretations.

How can OLR1/LOX-1 antibodies be used to investigate its role in tumor-associated macrophages?

Recent research has revealed OLR1's significant expression in tumor-associated macrophages (TAMs), particularly in head and neck squamous cell carcinoma (HNSCC). Researchers can employ the following methodological approaches to investigate this relationship:

This multifaceted approach can elucidate the functional significance of OLR1 in TAMs and its potential as both a prognostic marker and therapeutic target in cancer.

What strategies can be employed to investigate OLR1/LOX-1's role in cardiovascular disease using antibody-based approaches?

OLR1/LOX-1 has been strongly implicated in atherosclerosis and cardiovascular disease pathogenesis. Researchers investigating this relationship can implement these methodological approaches using OLR1 antibodies:

• Patient Serum Analysis: Measure soluble LOX-1 (sLOX-1) levels in patient serum using ELISA with OLR1-specific antibodies to identify correlations with inflammation markers and coronary plaque progression, particularly in inflammatory conditions like psoriasis .

• Atherosclerotic Plaque Immunohistochemistry: Analyze plaque composition and OLR1 expression patterns in human atherosclerotic samples using immunohistochemistry with OLR1 antibodies, with particular attention to macrophage-rich regions .

• In vitro Oxidized LDL Uptake Assays: Utilize fluorescently-labeled oxidized LDL in combination with OLR1 antibody blocking experiments to quantify OLR1-dependent uptake in endothelial cells and macrophages.

• Foam Cell Formation Studies: Investigate the role of OLR1 in foam cell formation by using OLR1 antibodies to block receptor function in macrophage cultures exposed to oxidized LDL.

• Vascular Cell Signaling Analysis: Employ OLR1 antibodies in immunoprecipitation experiments to isolate OLR1-containing signaling complexes, followed by proteomic analysis to identify interaction partners in response to oxidized LDL stimulation.

• OLR1-Targeted Imaging: Develop OLR1-targeted molecular imaging agents using labeled antibodies for non-invasive visualization of OLR1 expression in atherosclerotic plaques in animal models .

These approaches leverage antibody-based methods to comprehensively investigate OLR1's mechanistic contributions to cardiovascular pathology, potentially identifying new therapeutic targets and diagnostic markers.

How should researchers address potential discrepancies in OLR1/LOX-1 antibody-based experimental results?

When encountering discrepancies in OLR1/LOX-1 antibody-based experiments, researchers should systematically implement the following troubleshooting approaches:

• Antibody Validation Assessment: Re-evaluate antibody specificity through knockout/knockdown controls and blocking peptide competition assays. The search results describe established systems with OLR1 knockdown using shRNA and overexpression models that can serve as validation tools .

• Post-translational Modification Consideration: Investigate whether differences in post-translational modifications affect antibody recognition. OLR1/LOX-1 has a calculated molecular weight of approximately 31 kDa but is typically observed at 38-40 kDa due to glycosylation or other modifications .

• Isoform Analysis: Determine whether different OLR1/LOX-1 isoforms are present in your experimental system through RT-PCR with isoform-specific primers, followed by Western blot analysis with antibodies targeting different epitopes.

• Methodological Optimization: Systematically refine experimental protocols by titrating antibody concentrations, adjusting incubation times/temperatures, and testing different antigen retrieval methods for immunohistochemistry applications .

• Cross-validation with Multiple Detection Methods: Confirm findings using complementary techniques such as immunohistochemistry, Western blot, and RT-PCR to verify consistency across platforms.

• Alternative Antibody Evaluation: Compare results using antibodies from different sources or targeting different epitopes of OLR1/LOX-1. The search results mention multiple antibodies including polyclonal (A00760-1) and goat anti-human (AF1798) antibodies that could provide comparative data .

• External Validation: Compare results with published literature and, if possible, collaborate with laboratories experienced in OLR1/LOX-1 research to validate findings.

This systematic approach to troubleshooting can help resolve discrepancies and ensure robust, reproducible results in OLR1/LOX-1 research.

How can OLR1/LOX-1 antibodies be utilized in cancer research beyond traditional expression studies?

OLR1/LOX-1 antibodies offer numerous advanced applications in cancer research beyond basic expression analysis:

• Therapeutic Target Validation: Use OLR1 antibodies in preclinical models to evaluate the efficacy of OLR1 blockade in impeding tumor progression, particularly in cancers where OLR1 is highly expressed like HNSCC, where high OLR1 expression correlates with poor survival outcomes (Hazard Ratio = 1.724) .

• Tumor Microenvironment Immunophenotyping: Implement multiplexed immunofluorescence with OLR1 antibodies alongside markers for different immune cell populations to characterize the spatial distribution and phenotypic state of OLR1-expressing cells within the tumor microenvironment .

• Circulating Tumor Cell Detection: Develop methodologies using OLR1 antibodies to identify and isolate OLR1-expressing circulating tumor cells as potential biomarkers for metastatic disease.

• Patient Stratification for Clinical Trials: Create immunohistochemistry-based scoring systems using OLR1 antibodies to stratify patients for clinical trials testing OLR1-targeted therapies.

• Antibody-Drug Conjugates (ADCs): Explore the development of ADCs using OLR1 antibodies conjugated to cytotoxic agents for targeted delivery to OLR1-expressing cancer cells.

• Chimeric Antigen Receptor (CAR) T-cell Therapy: Investigate the potential of OLR1-targeted CAR T-cells using single-chain variable fragments derived from OLR1 antibodies for immunotherapy approaches.

These innovative applications leverage OLR1 antibodies beyond traditional expression studies to develop potentially transformative diagnostic and therapeutic strategies in oncology.

What are the technical considerations for developing in vivo imaging agents based on OLR1/LOX-1 antibodies?

Developing in vivo imaging agents based on OLR1/LOX-1 antibodies presents unique technical challenges and considerations:

• Antibody Fragment Selection: Full-length antibodies have long circulation times and slow tissue penetration. Consider using Fab, F(ab')2, or single-chain variable fragments (scFv) derived from OLR1 antibodies for improved pharmacokinetics and target-to-background ratios .

• Imaging Modality Compatibility: Different imaging modalities require specific labeling strategies:

  • For PET imaging: Conjugate OLR1 antibody fragments with chelators for radiometals such as 64Cu, 68Ga, or 89Zr

  • For optical imaging: Label with near-infrared fluorophores (NIR) for optimal tissue penetration

  • For MRI: Conjugate with gadolinium chelates or iron oxide nanoparticles

• Target Accessibility Assessment: Evaluate whether the OLR1 epitope remains accessible in vivo, particularly in atherosclerotic plaques or tumor microenvironments where the target may be partially obscured .

• Specificity Validation: Confirm in vivo specificity using appropriate controls including:

  • OLR1 knockout animal models

  • Pre-blocking with unlabeled antibodies

  • Non-targeting antibody fragments of similar size

• Biodistribution Studies: Characterize the non-specific accumulation in organs of clearance (liver, kidneys, spleen) to optimize signal-to-noise ratios and determine optimal imaging timepoints.

• Stability Evaluation: Assess the stability of the antibody-label conjugate in serum prior to in vivo application to ensure imaging signal accurately reflects target presence.

These technical considerations are critical for successfully developing OLR1-targeted imaging agents that could be valuable for non-invasive assessment of atherosclerotic plaques or OLR1-expressing tumors .

How can researchers optimize OLR1/LOX-1 antibody-based assays for biomarker development in clinical settings?

Translating OLR1/LOX-1 antibody-based assays into clinical biomarkers requires methodological optimization focusing on reproducibility, standardization, and clinical validation:

• Assay Platform Selection: Determine the most appropriate platform based on clinical requirements:

  • For high-throughput screening: Automated ELISA systems for soluble LOX-1 (sLOX-1) in serum samples

  • For tissue analysis: Standardized immunohistochemistry protocols compatible with clinical pathology workflows

  • For liquid biopsy applications: Flow cytometry or microfluidic-based capture of circulating cells expressing OLR1

• Reference Standard Development: Establish recombinant OLR1/LOX-1 protein standards with defined concentrations for accurate quantification and cross-laboratory standardization.

• Pre-analytical Variable Control: Standardize sample collection, processing, and storage procedures to minimize variability:

  • Define acceptable anticoagulants for blood collection

  • Establish consistent time windows between collection and processing

  • Implement standardized freeze-thaw protocols for stored samples

• Clinical Cutoff Determination: Analyze large, diverse patient cohorts to establish clinically meaningful cutoff values that correlate with disease states or outcomes, as demonstrated in studies correlating OLR1 expression with poor survival in HNSCC patients .

• Multiplex Biomarker Panels: Develop multiplex assays incorporating OLR1/LOX-1 alongside complementary biomarkers for improved diagnostic accuracy, particularly for complex diseases like atherosclerosis or cancer.

• Longitudinal Validation: Conduct prospective studies to evaluate the predictive value of OLR1/LOX-1 as a biomarker over time, particularly in response to therapeutic interventions.

• External Quality Assessment Programs: Implement proficiency testing programs to ensure consistency across different laboratories and testing personnel.

These methodological considerations are essential for successful translation of OLR1/LOX-1 antibody-based assays into clinically useful biomarkers that can impact patient management decisions .

What are the most promising future directions for OLR1/LOX-1 antibody applications in translational research?

The future of OLR1/LOX-1 antibody applications in translational research holds significant potential across multiple domains:

• Precision Medicine Applications: Development of companion diagnostic assays using OLR1 antibodies to identify patients most likely to benefit from therapies targeting OLR1 or related pathways, particularly in cardiovascular disease and cancer .

• Theranostic Approaches: Creation of dual-purpose OLR1 antibody conjugates that combine imaging capabilities with therapeutic effects for simultaneous diagnosis and treatment of atherosclerotic plaques or OLR1-expressing tumors .

• Immune Checkpoint Targeting: Investigation of OLR1 as a potential novel immune checkpoint, particularly in the tumor microenvironment where OLR1-expressing TAMs contribute to immunosuppression, with antibody-based blocking strategies to enhance anti-tumor immunity .

• Liquid Biopsy Development: Refinement of OLR1 antibody-based detection systems for circulating biomarkers including soluble OLR1, extracellular vesicles expressing OLR1, or circulating cells with OLR1 expression .

• Multiomics Integration: Correlation of OLR1 antibody-based protein detection with genomic, transcriptomic, and metabolomic data to develop integrated biomarker signatures for complex diseases.

• Early Disease Detection: Development of highly sensitive assays using optimized OLR1 antibodies for detecting subclinical atherosclerosis or early-stage cancer based on subtle alterations in OLR1 expression patterns .

These promising directions highlight the expanding role of OLR1/LOX-1 antibodies in bridging fundamental research with clinical applications, potentially transforming disease diagnosis, monitoring, and treatment strategies across multiple medical disciplines.

What standardization efforts are needed to improve reproducibility in OLR1/LOX-1 antibody-based research?

Improving reproducibility in OLR1/LOX-1 antibody-based research requires coordinated standardization efforts across multiple dimensions:

• Antibody Validation Standards: Implement comprehensive validation requirements including:

  • Knockout/knockdown controls

  • Multiple epitope targeting

  • Cross-platform verification

  • Detailed reporting of validation methods in publications

• Reporting Guidelines: Develop specialized reporting guidelines for OLR1/LOX-1 research that mandate disclosure of:

  • Complete antibody characteristics (clone, lot, epitope)

  • Detailed experimental protocols including antibody concentration, incubation conditions, and detection methods

  • Positive and negative controls employed

  • Raw data availability guidelines

• Reference Materials Development: Establish internationally recognized reference materials including:

  • Purified recombinant OLR1/LOX-1 protein standards

  • Standardized positive control cell lines or tissues

  • Verified OLR1/LOX-1 knockout cell lines for negative controls

• Method Harmonization: Create consensus protocols for common applications such as:

  • Immunohistochemistry procedures for OLR1/LOX-1 detection in different tissue types

  • Western blot protocols accounting for the discrepancy between expected (31 kDa) and observed (38-40 kDa) molecular weights

  • ELISA methods for soluble OLR1/LOX-1 quantification in biological fluids

• Interlaboratory Proficiency Testing: Implement regular proficiency testing programs where multiple laboratories analyze identical samples using their OLR1/LOX-1 antibody-based methods and compare results.

These standardization efforts would significantly enhance data reproducibility and reliability across different research groups, accelerating scientific progress in OLR1/LOX-1 research and facilitating more effective translation to clinical applications.

How might advances in antibody engineering impact future OLR1/LOX-1 research and clinical applications?

Emerging antibody engineering technologies promise to revolutionize OLR1/LOX-1 research and clinical applications through several innovative approaches:

• Bispecific Antibodies: Development of bispecific antibodies targeting OLR1/LOX-1 and complementary targets (e.g., OLR1 and CD40L for atherosclerosis, or OLR1 and PD-1 for cancer) to simultaneously modulate multiple disease-relevant pathways.

• Intrabodies and Nanobodies: Engineering of small-format antibodies capable of intracellular expression or enhanced tissue penetration to better access OLR1/LOX-1 in difficult-to-reach compartments or tissues.

• pH-Sensitive Antibodies: Design of antibodies that selectively release therapeutic payloads in the acidic microenvironment of atherosclerotic plaques or tumors after OLR1/LOX-1-mediated internalization.

• Site-Specific Conjugation: Implementation of advanced conjugation chemistries that preserve OLR1/LOX-1 antibody binding properties while enabling precise attachment of imaging agents or therapeutic molecules.

• Antibody-Based Chimeric Antigen Receptor (CAR) Constructs: Development of OLR1-targeted CAR T-cell therapies for treating cancers with elevated OLR1 expression or abundant OLR1+ tumor-associated macrophages .

• Humanized and Fully Human Antibodies: Creation of humanized or fully human OLR1/LOX-1 antibodies with reduced immunogenicity for in vivo therapeutic applications, improving on currently available rabbit and goat polyclonal antibodies described in the search results .

• In Silico Antibody Design: Utilization of computational approaches to design antibodies with enhanced specificity for different OLR1/LOX-1 epitopes or isoforms, enabling more precise targeting of disease-relevant forms of the receptor.